Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
about
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.Quality of life in Arab women with breast cancer: a review of the literatureHow could patient reported outcomes improve patient management in chronic myeloid leukemia?Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Health related quality of life in patients with multiple myeloma undergoing a double transplantation.Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation.Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.How oncologists and their patients with advanced cancer communicate about health-related quality of life.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: current challenges and future applicationsEffect of patient and patient-oncologist relationship characteristics on communication about health-related quality of life.Quality of life and supportive care in multiple myeloma.Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools.Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.Patient-Reported Physical Function Measures in Cancer Clinical Trials.Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer.Predicting survival in advanced hematologic malignancies: do patient-reported symptoms matter?Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study.Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma.Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation.Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial.
P2860
Q22241762-B388973C-1205-4D96-B40D-008D1DFDB9D2Q26749529-B743E20C-10C0-487F-AECE-7B2D3C7CFE01Q30241092-BCBA49FD-3B9E-4C6B-9BBA-96BA36F747FBQ30486842-8C24FA8C-E8C9-4ADC-ADA4-8B6719A76356Q30650394-4D9314B8-32B1-4E08-8C6B-1D93D8EFECD5Q30964688-A5B2AE57-7C74-43A8-A9E8-E1E1D30E9BCCQ33210966-BEBA88AD-E763-4068-8B5C-B8318E0504F1Q33583301-89D1D94E-FCB8-43B9-9441-19614E71CF7BQ33596402-824D8B6B-2958-4579-87FB-D8985D9ABBD3Q34095653-7A4C8A61-15B7-4A6F-88AF-126587412103Q34953938-0EDC7B2F-4631-47B3-B2D8-3766B0E943C0Q35669893-847C6613-BAB7-48E5-BBED-B82936401BF7Q36447635-165804CA-DFC6-43AE-9817-0E10C887B9F1Q36498336-A636B5C8-D66C-46C9-8BB8-CCA4167FB3B3Q36709268-957AC6BC-4306-45D3-8A12-A45FE2A3F835Q37426566-18C956B8-DCE6-4B50-BAF0-F47B1DA9B53CQ37682654-3FDF49D2-D35D-4908-9616-6A746DDEC1A6Q38044063-B370E818-E2FC-463B-883D-552B3F94F6C5Q38232055-0AE71AE8-3F29-470B-BAF9-D8A3254F7E6EQ38459634-7E4F66B1-1407-4379-89D5-07975E3C7AECQ39270037-ECAD0198-5DA7-4A5F-8B19-8E1F30031440Q39416134-5FD47073-6E47-49EA-911C-2B2AA5AC0877Q41601940-B94A76E5-AD2D-4E8E-A83B-AE5E461570C4Q45326786-F9E95A80-FF9C-499B-9986-F2D8234B97E5Q48423123-DD6C389A-7D93-4E15-9986-9151A3E5F5C4Q48433004-3B227877-6229-47F0-9559-D10FA330FE83Q48459753-CA9AE299-4814-4E8E-A70A-FE3B15421603Q51564235-E911AE49-871C-44AA-915D-B9EF539A5541Q51920465-4E474021-32F7-410B-B595-95FF2FF8311EQ53531302-78AF6787-A994-4BE5-AF84-D206EF089535
P2860
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Health-related quality of life ...... a. Nordic Myeloma Study Group.
@en
type
label
Health-related quality of life ...... a. Nordic Myeloma Study Group.
@en
prefLabel
Health-related quality of life ...... a. Nordic Myeloma Study Group.
@en
P1476
Health-related quality of life ...... a. Nordic Myeloma Study Group.
@en
P2093
P356
10.1046/J.1365-2141.1997.222667.X
P407
P577
1997-04-01T00:00:00Z